Hyunjin J Kim, MD
Ophthalmology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kim’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A116168 · Current
Licensed to practise in California · since 2011 · expires 2028-08-31 · Umdnj Robert Wood Johnson Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$163,243
Medicare paid this office $163,243 for 522 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 281 | $43,529 | $113 |
| New patient visit (45+ min) | 183 | $24,101 | $132 |
| Long return visit (40+ min) | 73 | $11,598 | $151 |
| Insertion of probe into nasal tear duct | 33 | $6,869 | $196 |
| Biopsy of eyelid | 31 | $5,563 | $179 |
See all 20 services
| Return visit (30+ min) | 281 | $43,529 | $113 |
| New patient visit (45+ min) | 183 | $24,101 | $132 |
| Long return visit (40+ min) | 73 | $11,598 | $151 |
| Insertion of probe into nasal tear duct | 33 | $6,869 | $196 |
| Biopsy of eyelid | 31 | $5,563 | $179 |
| Probing of nasal tear duct | 30 | $4,287 | $134 |
| Short return visit (20+ min) | 46 | $4,087 | $80 |
| Imaging of retina | 95 | $3,911 | $40 |
| Photography of content of eyes | 143 | $3,822 | $24 |
| New patient visit (60+ min) | 19 | $3,647 | $192 |
| Exam of visual field with extended testing | 53 | $3,421 | $62 |
| Imaging of optic nerve | 92 | $3,271 | $34 |
| Established patient complete exam of visual system | 20 | $2,477 | $118 |
| Exam of visual field with limited testing | 48 | $1,503 | $31 |
| Photography of the retina | 26 | $940 | $35 |
| Injection into skin growth, 1-7 growths | 13 | $697 | $50 |
| Removal of eyelashes using forceps | 22 | $520 | $15 |
| Exam of the internal drainage system of eye | 12 | $298 | $25 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 16 | $238 | $14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $44 | None |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal or shaving of skin growth | 1-10 | None |
Who their Medicare patients are
522 Original Medicare patients in 2024. Average age 76 · Women 61% · Also on Medicaid 8% · Health risk score 0.89. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 57% · Diabetes 23% · Coronary heart disease 21% · Cancer 17% · Chronic kidney disease 16% · Depression 13% · Atrial fibrillation 11% · Heart failure 10% · COPD 5% · Dementia 4% · Stroke 3%.
The office billed $749,778, Medicare allowed $220,042 and paid $163,243; for 1,945 services of 62 kinds; $1,765 of it was for drugs given in the office and $161,478 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 522 | 1,945 | 76 | 0.89 | $749,778 | $163,243 |
| 2023 | 175 | 366 | 76 | 0.85 | $144,887 | $37,237 |
| 2013 | 65 | 97 | 74 | 1.36 | $55,549 | $7,055 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 85 | $10,989 | $118 |
| New patient visit (45+ min) | 53 | $8,048 | $152 |
| Probing of nasal tear duct | 19 | $2,540 | $134 |
| Long return visit (40+ min) | 14 | $2,321 | $166 |
| Short return visit (20+ min) | 15 | $1,527 | $85 |
| Imaging of retina | 27 | $1,045 | $39 |
| Photography of content of eyes | 25 | $611 | $24 |
| Exam of visual field with limited testing | 13 | $424 | $33 |
2013: 2 services
| Established patient problem focused exam of visual system | 44 | $1,813 | $39 |
| New patient problem focused exam of visual system | 13 | $494 | $38 |
Drugs they prescribed that Part D paid
$66,245
Pharmacies billed $66,245 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
429 generic and fewer than 11 brand-name prescriptions · $66,245 in drug cost · 47 antibiotic prescriptions to 42 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 25 | $21,879 | $875 |
| Miebo | 14 | $13,415 | $958 |
| Cyclosporine | 11 | $5,724 | $520 |
| Erythromycin | 236 | $2,615 | $11 |
| Neomycin-Polymyxin-Dexameth | 67 | $680 | $10 |
See all 12 drugs
| Restasis | 25 | $21,879 | $875 |
| Miebo | 14 | $13,415 | $958 |
| Cyclosporine | 11 | $5,724 | $520 |
| Erythromycin | 236 | $2,615 | $11 |
| Neomycin-Polymyxin-Dexameth | 67 | $680 | $10 |
| Prednisolone Acetate | 12 | $556 | $46 |
| Doxycycline Hyclate | 22 | $552 | $25 |
| Azelastine | 11 | $431 | $39 |
| Latanoprost | 27 | $379 | $14 |
| Dorzolamide-Timolol | 11 | $238 | $22 |
| Amoxicillin-Clavulanate Potass | 12 | $93 | $8 |
| Azithromycin | 12 | $57 | $5 |
Year by year
| 2024 | 572 | 292 | None | None | $66,245 |
| 2023 | 506 | 257 | 7% (35) | 12% | $18,524 |
| 2022 | 687 | 245 | 13% (92) | 10% | $34,362 |
| 2021 | 591 | 222 | 13% (74) | 14% | $36,451 |
| 2020 | 573 | 183 | 11% (63) | 18% | $43,984 |
| 2019 | 713 | 226 | 12% (85) | 15% | $58,124 |
| 2018 | 634 | 208 | 15% (97) | 16% | $52,641 |
| 2017 | 618 | 199 | 16% (96) | 15% | $47,807 |
| 2016 | 509 | 191 | 19% (96) | 11% | $44,398 |
| 2015 | 356 | 150 | 14% (48) | 8% | $24,662 |
| 2014 | 452 | 178 | 13% (59) | 4% | $29,822 |
| 2013 | 259 | 100 | 20% (52) | 5% | $11,169 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Retin-A Micro | 11 | $4,885 | $444 |
| Erythromycin | 212 | $4,264 | $20 |
| Cyclosporine | 24 | $3,365 | $140 |
| Olopatadine | 70 | $1,507 | $22 |
| Neomycin-Polymyxin-Dexameth | 29 | $425 | $15 |
| Hydrocodone-Acetaminophen | 34 | $220 | $6 |
| Metronidazole | 12 | $176 | $15 |
2022: 11 drugs
| Cequa | 19 | $12,190 | $642 |
| Retin-A Micro | 12 | $5,329 | $444 |
| Erythromycin | 244 | $5,076 | $21 |
| Olopatadine | 109 | $2,105 | $19 |
| Doxycycline Monohydrate | 36 | $785 | $22 |
| Hydrocodone-Acetaminophen | 87 | $609 | $7 |
| Retin-A | 13 | $595 | $46 |
| Neomycin-Polymyxin-Dexameth | 19 | $273 | $14 |
| Azelastine | 12 | $201 | $17 |
| Ondansetron Odt | 22 | $192 | $9 |
| Amoxicillin-Clavulanate Potass | 11 | $191 | $17 |
2021: 9 drugs
| Cequa | 35 | $18,414 | $526 |
| Erythromycin | 175 | $3,461 | $20 |
| Zioptan | 12 | $2,990 | $249 |
| Olopatadine | 131 | $1,863 | $14 |
| Hydrocodone-Acetaminophen | 66 | $505 | $8 |
| Neomycin-Polymyxin-Dexameth | 22 | $373 | $17 |
| Dorzolamide-Timolol | 11 | $368 | $33 |
| Doxycycline Monohydrate | 15 | $298 | $20 |
| Cephalexin | 14 | $158 | $11 |
2020: 9 drugs
| Restasis | 34 | $20,879 | $614 |
| Erythromycin | 142 | $3,826 | $27 |
| Retin-A Micro | 14 | $2,919 | $208 |
| Olopatadine | 154 | $2,811 | $18 |
| Fluorometholone | 12 | $1,422 | $118 |
| Retin-A | 15 | $820 | $55 |
| Doxycycline Monohydrate | 26 | $490 | $19 |
| Hydrocodone-Acetaminophen | 57 | $404 | $7 |
| Neomycin-Polymyxin-Dexameth | 14 | $228 | $16 |
2019: 11 drugs
| Restasis | 48 | $28,194 | $587 |
| Bacitracin | 57 | $12,328 | $216 |
| Fluorometholone | 27 | $3,433 | $127 |
| Erythromycin | 98 | $2,964 | $30 |
| Olopatadine | 159 | $2,674 | $17 |
| Neomycin-Polymyxin-Dexameth | 66 | $1,658 | $25 |
| Retin-A | 22 | $1,499 | $68 |
| Doxycycline Monohydrate | 26 | $652 | $25 |
| Hydrocodone-Acetaminophen | 79 | $500 | $6 |
| Bacitracin-Polymyxin | 12 | $183 | $15 |
| Cephalexin | 11 | $95 | $9 |
2018: 10 drugs
| Restasis | 43 | $22,603 | $526 |
| Bacitracin | 75 | $15,792 | $211 |
| Fluorometholone | 22 | $2,320 | $105 |
| Retin-A | 27 | $2,120 | $79 |
| Neomycin-Polymyxin-Dexameth | 70 | $1,871 | $27 |
| Olopatadine | 144 | $1,607 | $11 |
| Erythromycin | 54 | $1,152 | $21 |
| Acetaminophen-Codeine | 38 | $481 | $13 |
| Hydrocodone-Acetaminophen | 56 | $391 | $7 |
| Doxycycline Monohydrate | 13 | $314 | $24 |
2017: 9 drugs
| Bacitracin | 96 | $21,089 | $220 |
| Restasis | 21 | $9,516 | $453 |
| Olopatadine | 120 | $2,166 | $18 |
| Neomycin-Polymyxin-Dexameth | 72 | $1,995 | $28 |
| Retin-A | 28 | $1,993 | $71 |
| Fluorometholone | 12 | $1,438 | $120 |
| Acetaminophen-Codeine | 86 | $1,225 | $14 |
| Erythromycin | 45 | $994 | $22 |
| Doxycycline Monohydrate | 19 | $556 | $29 |
2016: 9 drugs
| Bacitracin | 115 | $25,877 | $225 |
| Restasis | 17 | $7,336 | $432 |
| Neomycin-Polymyxin-Dexameth | 62 | $1,428 | $23 |
| Acetaminophen-Codeine | 93 | $1,382 | $15 |
| Erythromycin | 43 | $1,095 | $25 |
| Doxycycline Monohydrate | 24 | $933 | $39 |
| Olopatadine | 24 | $894 | $37 |
| Fluticasone Propionate | 14 | $243 | $17 |
| Cephalexin | 12 | $162 | $14 |
2015: 8 drugs
| Bacitracin | 91 | $14,782 | $162 |
| Neomycin-Polymyxin-Dexameth | 70 | $1,839 | $26 |
| Doxycycline Monohydrate | 32 | $1,419 | $44 |
| Erythromycin | 28 | $725 | $26 |
| Bacitracin-Polymyxin | 11 | $466 | $42 |
| Hydrocodone-Acetaminophen | 22 | $391 | $18 |
| Acetaminophen-Codeine | 26 | $368 | $14 |
| Cephalexin | 16 | $238 | $15 |
2014: 7 drugs
| Bacitracin | 149 | $18,277 | $123 |
| Doxycycline Monohydrate | 58 | $2,498 | $43 |
| Erythromycin | 47 | $1,346 | $29 |
| Neomycin-Polymyxin-Dexameth | 41 | $851 | $21 |
| Cephalexin | 31 | $476 | $15 |
| Hydrocodone-Acetaminophen | 46 | $399 | $9 |
| Ondansetron Odt | 13 | $364 | $28 |
2013: 5 drugs
| Bacitracin | 76 | $5,770 | $76 |
| Erythromycin | 24 | $466 | $19 |
| Neomycin-Polymyxin-Dexameth | 23 | $439 | $19 |
| Hydrocodone-Acetaminophen | 48 | $394 | $8 |
| Cephalexin | 27 | $362 | $13 |
Money from drug and device companies
$25 in 2025
| 2025 | 1 | 1 | None | $25 |
| 2023 | 2 | 2 | None | $218 |
| 2019 | 1 | 1 | None | $108 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $25 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-10-22 | Tepezza | $25 |
See earlier years (2023, 2019)
2023: $218
| Horizon Therapeutics plc | Tepezza | $150 | 1 payment
|
| Stryker | Xpress Ent Dilation System | $68 | 1 payment
|
2019: $108
| Galderma Laboratories L.P. | None | $108 | 1 payment
|
Professional record
- NPI
- 1376765990
- Licence
- CA A116168California A116168: Current · expires 2028-08-31
- Trained
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc), 2006
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-05-03
- NPI last updated
- 2023-08-25
- NPI record certified
- 2023-08-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3553 Whipple Rd, Union City, CA, 94587
This office lists an electronic records connection.